Empirical treatment of febrile neutropenia: Evolution of current therapeutic approaches

Clinical Infectious Diseases

Volumn 24, Issue SUPPL. 2, 1997, Pages

  Hathorn, James W ^a,b   Lyke, Kirsten ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BIOLOGICAL RESPONSE MODIFIER; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFALOTIN; CEFOPERAZONE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; COLONY STIMULATING FACTOR; COTRIMOXAZOLE; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL TRIAL; DIARRHEA; FEVER; FUNGEMIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; REVIEW; SEIZURE;

EID: 0030936123     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.supplement_2.s256     Document Type: Review

References (12)

1. Hughes WT, Armstrong D, Bodey GP, et al. from the Working Committee, Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-96.
2. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-8.
3. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119:584-93.
4. Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1990;34:1336-41.
5. Rolston KVI, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152:283-91.
6. Lee JW, Pizzo PA. Management of the cancer patient with fever and prolonged neutropenia. Hematol Oncol Clin North Am 1993; 7: 937-60.
7. Hathorn JW. Empirical antibiotics for febrile neutropenic cancer patients. Eur J Cancer Clin Oncol 1989;25(suppl 2):S43-51.
8. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
9. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
10. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-5.
11. Klastersky J. A review of chemoprophylaxis and therapy of bacterial infections in neutropenic patients. Diagn Microbiol Infect Dis 1989; 12(suppl 4):201S-7S.
12. Klastersky J, Glauser MP, Schmipff SC, Zinner SH, Gaya H, and the European Organisation for Research on Treatment of Cancer Antimicrobial Therapy Project Group. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986; 29:263-70.